Axogen, Inc. Completes Acquisition of BioCircuit Technologies

What Happened

• Axogen, Inc. announced the completion of its previously disclosed acquisition of BioCircuit Technologies, Inc. and filed a Form 8-K (Item 7.01, Regulation FD Disclosure) to furnish a press release about the closing. The press release is attached as Exhibit 99.1 to the 8-K dated October 1, 2026. The filing was signed by Marc Began, Executive VP, General Counsel and Chief Compliance Officer.

Key Details

• Transaction announced as closed: Axogen completed its acquisition of BioCircuit Technologies, Inc. (date in filing: October 1, 2026).
• Disclosure format: Press release furnished as Exhibit 99.1 to the Form 8-K (Item 7.01); Exhibit listing also appears under Item 9.01.
• Filing executed by: Marc Began, Axogen EVP, General Counsel and Chief Compliance Officer, dated October 1, 2026.
• The 8-K does not include financial terms or detailed financial statements for the acquisition in the furnished press release.

Why It Matters

• This 8-K notifies investors that Axogen has completed a strategic acquisition, a corporate event that may affect the company's products, operations or financial results. Because the filing furnishes only a press release and does not disclose purchase price or financial impact, investors should review the press release and monitor Axogen's future SEC filings (e.g., subsequent 8-Ks, 10-Q, or 10-K) for material financial details and integration plans.